镓标记的DOTA-TATE与镓标记的DOTA-JR11 PET/CT在肿瘤性骨软化症患者中的头对头比较：一项前瞻性研究。
Head-to-Head Comparison of Ga-DOTA-TATE and Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study.
作者信息
Hou Guozhu, Zhang Yuwei, Liu Yu, Wang Peipei, Xia Weibo, Xing Xiaoping, Huo Li, Li Fang, Jing Hongli
机构信息
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
出版信息
Front Oncol. 2022 Feb 24;12:811209. doi: 10.3389/fonc.2022.811209. eCollection 2022.
BACKGROUND
The purpose of this study is to compare the sensitivity of Ga-DOTA-JR11 and Ga-DOTA-TATE PET/CT for detecting the responsible tumor of tumor-induced osteomalacia (TIO) and investigate if Ga-DOTA-JR11 PET/CT can identify the culprit tumor of TIO in multiple suspicious lesions in Ga-DOTA-TATE PET/CT.
METHODS
A total of 19 patients with suspected TIO were prospectively recruited in this study. Each patient underwent whole-body PET/CT scan 40-60 min postinjection using Ga-DOTA-TATE and Ga-DOTA-JR11 on the same PET/CT, respectively in sequence, and on consecutive days. The diagnosis of TIO was confirmed by the combination of the postsurgical pathological results of the tumor and clinical information.
RESULTS
Among the 19 patients with TIO who were included in this study, culprit tumors from all patients were confirmed pathologically. Ga-DOTA-TATE PET/CT positively identified the causative tumor in 18/19 patients, whereas Ga-DOTA-JR11 PET/CT was positive in 11/19 patients (94.7% vs. 57.9%, respectively; < 0.05). Ga-DOTA-TATE PET/CT demonstrated more than one increased focal activity in 7 patients for a total of 16 lesions (3 lesions each in 2 patients and 2 lesions each in the rest 5 patients). However, seven of these 16 lesions showed concordant results on Ga-DOTA-JR11 PET/CT by demonstrating increased activity (one lesion in each of the 7 patients). The surgical specimens of the lesions in these 7 patients confirmed the phosphaturic mesenchymal tumor. A total of 11 culprit tumors were positive in both Ga-DOTA-TATE and Ga-DOTA-JR11 PET/CT. The SUVmax of 11 culprit tumors was significantly higher on Ga-DOTA-TATE PET/CT compared with that on Ga-DOTA-JR11 PET/CT (17.8 ± 12.5 vs. 6.8 ± 6.2; < 0.05).
CONCLUSIONS
Ga-DOTA-TATE PET/CT is more sensitive to Ga-DOTA-JR11 PET/CT in the detection of the culprit tumor of TIO. However, Ga-DOTA-JR11 PET/CT might be helpful to identify the tumor in multiple suspicious lesions in Ga-DOTA-TATE PET/CT.
CLINICAL TRIAL REGISTRATION
clinicaltrials.gov, identifier NCT04689893.
背景
本研究的目的是比较镓标记的DOTA-JR11和镓标记的DOTA-TATE PET/CT对肿瘤性骨软化症（TIO）责任肿瘤的检测敏感性，并研究镓标记的DOTA-JR11 PET/CT能否在镓标记的DOTA-TATE PET/CT的多个可疑病变中识别出TIO的罪魁祸首肿瘤。
方法
本研究前瞻性纳入了19例疑似TIO患者。每位患者在注射镓标记的DOTA-TATE和镓标记的DOTA-JR11后40 - 60分钟，分别在同一台PET/CT上按顺序且连续两天进行全身PET/CT扫描。TIO的诊断通过肿瘤的术后病理结果与临床信息相结合来确定。
结果
本研究纳入的19例TIO患者中，所有患者的罪魁祸首肿瘤均经病理证实。镓标记的DOTA-TATE PET/CT在19例患者中的18例中阳性识别出致病肿瘤，而镓标记的DOTA-JR11 PET/CT在19例患者中的11例中呈阳性（分别为94.7%对57.9%；P < 0.05）。镓标记的DOTA-TATE PET/CT在7例患者中显示出不止一处局灶性活性增加，共16个病灶（2例患者各有3个病灶，其余5例患者各有2个病灶）。然而，这16个病灶中的7个在镓标记的DOTA-JR11 PET/CT上显示出活性增加的一致结果（7例患者各有1个病灶）。这7例患者病变的手术标本证实为磷酸尿性间叶肿瘤。共有11个罪魁祸首肿瘤在镓标记的DOTA-TATE和镓标记的DOTA-JR11 PET/CT上均为阳性。11个罪魁祸首肿瘤的最大标准摄取值在镓标记的DOTA-TATE PET/CT上显著高于镓标记的DOTA-JR11 PET/CT（分别为17.8 ± 12.5对6.8 ± 6.2；P < 0.05）。
结论
在检测TIO的罪魁祸首肿瘤方面，镓标记的DOTA-TATE PET/CT比镓标记的DOTA-JR11 PET/CT更敏感。然而，镓标记的DOTA-JR11 PET/CT可能有助于在镓标记的DOTA-TATE PET/CT的多个可疑病变中识别肿瘤。
临床试验注册
clinicaltrials.gov，标识符NCT04689893。
Zotero 插件